The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While both classes demonstrate remarkable efficacy in promoting glycemic control and facilitating substantial weight reduction, key diff

In the ever-evolving landscape of diabetes management, a novel approach is emerging that focuses on specifically targeting glucose levels. This innovative strategy involves leveraging the power of two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP have shown promising results in